These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19158152)

  • 1. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
    Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
    Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
    Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
    Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
    Kivikko M; Pollesello P; Tarvasmäki T; Sarapohja T; Nieminen MS; Harjola VP
    Int J Cardiol; 2016 Jul; 215():26-31. PubMed ID: 27107540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
    Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J; Giamouzis G; Giannakoulas G
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
    [No Abstract]   [Full Text] [Related]  

  • 14. Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?
    Omerovic E; Waagstein F; Swedberg K
    Eur J Heart Fail; 2010 Apr; 12(4):313-4. PubMed ID: 20335348
    [No Abstract]   [Full Text] [Related]  

  • 15. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to treat acute decompensated heart failure in the 'beta-blocker era'?
    Marcondes-Braga FG; Mangini S; Ayub-Ferreira SM; Bocchi EA; Bacal F
    Eur J Heart Fail; 2010 Aug; 12(8):893-4. PubMed ID: 20675672
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
    J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.